A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits

Vaccine

Volumn 30, Issue 44, 2012, Pages 6263-6269

  Lipinski, Tomasz ^a   Wu, Xiangyang ^a   Sadowska, Joanna ^a   Kreiter, Erin ^a   Yasui, Yutaka ^a   Cheriaparambil, Shilton ^b   Rennie, Robert ^b   Bundle, David R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Antibody mediated clearance of Candida albicans; Candida albicans beta mannan trisaccharide epitope; Cyclophosphamide; Immunocompromised rabbit Candida model; Trisaccharide tetanus toxoid conjugate vaccine

Indexed keywords

ANTISERUM; BETA MANNAN TRISACCHARIDE CONJUGATE VACCINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TETANUS TOXOID; TRISACCHARIDE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL WALL; CONFOCAL MICROSCOPY; DRUG ACTIVITY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; IMMUNITY; IMMUNOCOMPETENCE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, FUNGAL; BLOOD; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; COMPLEMENT C3; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGAL VACCINES; FUNGEMIA; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MANNANS; RABBITS; TETANUS TOXOID; TREATMENT OUTCOME; TRISACCHARIDES; VACCINES, CONJUGATE;

EID: 84865724160     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.010     Document Type: Article

References (49)

1. Monitoring hospital-acquired infections to promote patient safety - United States, 1990-1999. Morb Mortal Wkly Rep 2000, 49:149-153.
2. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999, 29:239-244.
3. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989, 149:2349-2353.
4. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
5. Maksymiuk A.W., Thongprasert S., Hopfer R., Luna M., Fainstein V., Bodey G.P. Systemic candidiasis in cancer-patients. Am J Med 1984, 77:20-27.
6. Crawford S.W. Bone-marrow transplantation and related infections. Semin Respir Infect 1993, 8:183-190.
7. Espinel-Ingroff A., Pfaller M.A. Antifungal agents and susceptibility testing. Manual of clinical microbiology 1995, 1405-1414. American Society for Microbiology, Washington, DC. 6th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
8. Casadevall A., Pirofski L.A. Polysaccharide-containing conjugate vaccines for fungal diseases. Trends Mol Med 2006, 12:6-9.
9. Cutler J.E., Deepe G.S., Klein B.S. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007, 5:13-28.
10. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005, 202:597-606.
11. Xin H., Dziadek S., Bundle D.R., Cutler J.E. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008, 105:13526-13531.
12. Karlowsky J.A., Zhanel G.G., Klym K.A., Hoban D.J., Kabani A.M. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997, 29:5-9.
13. Taylor G.D., Buchananchell M., Kirkland T., Mckenzie M., Wiens R. Trends and sources of nosocomial fungemia. Mycoses 1994, 37:187-190.
14. Thaler M., Pastakia B., Shawker T.H., Oleary T., Pizzo P.A. Hepatic candidiasis in cancer-patients - the evolving picture of the syndrome. Ann Intern Med 1988, 108:88-100.
15. Yamamura D.L.R., Rotstein C., Nicolle L.E., Ioannou S., Johnston L., Schlech W., et al. Candidemia at selected Canadian sites: results from the fungal disease registry, 1992-1994. Can Med Assoc J 1999, 160:493-499.
16. Casadevall A. Antibody immunity and invasive fungal-infections. Infect Immun 1995, 63:4211-4218.
17. Casadevall A., Cassone A., Bistoni F., Cutler J.E., Magliani W., Murphy J.W., et al. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute?. Med Mycol 1998, 36:95-105.
18. Cutler J.E., Granger B.L., Han Y. Immunoprotection against candidiasis. Candida and candidiasis 2002, ASM Press, Washington, DC. R.A. Calderone (Ed.).
19. Matthews R., Burnie J. Antibodies against Candida: potential therapeutics. Trends Microbiol 1996, 4:354-358.
20. Bromuro C., Romano M., Chiani P., Berti F., Tontini M., Proietti D., et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010, 28:2615-2623.
21. Kent H.L. Epidemiology of vaginitis. Am J Obstet Gynecol 1991, 165:1168-1176.
22. Clancy R., Corrigan E., Dunkley M., Eyers F., Beagley K. Recurrent vulvovaginal candidiasis - allergy or immune deficiency. Int Arch Allergy Immunol 1999, 118:349-350.
23. Fidel P.L., Sobel J.D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996, 9:335.
24. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun 1999, 67:826-833.
25. Mochon A.B., Cutler J.E. Is a vaccine needed against Candida albicans. Med Mycol 2006, 44:197.
26. Bromuro C., Torosantucci A., Chiani P., Conti S., Polonelli L., Cassone A. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect Immun 2002, 70:5462-5470.
27. Cutler J.E. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 2005, 5:383-392.
28. Cassone A. Cell wall of Candida albicans: its functions and its impact on the host. Curr Top Med Mycol 1989, 3:248-314.
29. Chaffin W.L., Skudlarek J., Morrow K.J. Variable expression of a surface determinant during proliferation of Candida albicans. Infect Immun 1988, 56:302-309.
30. 13C NMR analyses of acid-labile oligomannosyl residues. Arch Biochem Biophys 1990, 278:195-204.
31. Shibata N., Ikuta K., Imai T., Satoh Y., Satoh R., Suzuki A., et al. Existence of branched side-chains in the cell-wall mannan of pathogenic yeast, Candida albicans - structure-antigenicity relationship between the cell-wall mannans of Candida albicans and Candida parapsilosis. J Biol Chem 1995, 270:1113-1122.
32. Han Y.M., Morrison R.P., Cutler J.E. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998, 66:5771-5776.
33. Han Y.M., Cutler J.E. Antibody-response that protects against disseminated candidiasis. Infect Immun 1995, 63:2714-2719.
34. Han Y., Ulrich M.A., Cutler J.E. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 1999, 179:1477-1484.
35. Xin H., Cartmell J., Bailey J.J., Dziadek S., Bundle D.R., Cutler J.E. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 2012, 7:e35106.
36. Han Y., Riesselman M.H., Cutler J.E. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 2000, 68:1649-1654.
37. Nitz M., Ling C.C., Otter A., Cutler J.E., Bundle D.R. The unique solution structure and immunochemistry of the Candida albicans beta-1,2-mannopyranan cell wall antigens. J Biol Chem 2002, 277:3440-3446.
38. Johnson M.A., Cartmell J., Weisser N.E., Woods R.J., Bundle D.R. Molecular recognition of Candida albicans (1→2)-β-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residue. J Biol Chem 2012, 287:18078-18090.
39. Phalipon A., Costachel C., Grandjean C., Thuizat A., Guerreiro C., Tanguy M., et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J Immunol 2006, 176:1686-1694.
40. Pozsgay V., Kubler-Kielb J., Schneerson R., Robbins J.B. Effect of the nonreducing end of Shigella dysenteriae type 10-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci U S A 2007, 104:14478-14482.
41. Benaissa-Trouw B., Lefeber D.J., Kamerling J.P., Vliegenthart J.F.G., Kraaijeveld K., Snippe H. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM197 conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect Immun 2001, 69:4698-4701.
42. Safari D., Dekker H.A.T., Joosten J.A.F., Michalik D., de Souza A.C., Adamo R., et al. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect Immun 2008, 76:4615-4623.
43. Wu X., Bundle D.R. Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology. J Org Chem 2005, 70:7381-7388.
44. Goding J.W. Monoclonal antibodies: principles and practice: production and application of monoclonal antibodies in cell biology, biochemistry and immunology 1983, Academic Press, Inc., London, p. 60.
45. Kanbe T., Han Y.M., Redgrave B., Riesselman M.H., Culter J.E. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph-node tissue. Infect Immun 1993, 61:2578-2584.
46. Walsh T.J., Bacher J., Pizzo P.A. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 1988, 38:467-471.
47. Liang K.Y., Zeger S.L. Longitudinal data-analysis using generalized linear-models. Biometrika 1986, 73:13-22.
48. Han Y.M., Kozel T.R., Zhang M.X., MacGill R.S., Carroll M.C., Cutler J.E. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 2001, 167:1550-1557.
49. Lindberg A.A., Wollin R., Bruse G., Ekwall E., Svenson S.B. Immunology and immunochemistry of synthetic and semisynthetic salmonella O-antigen-specific glycoconjugates. ACS Symp Ser 1983, 231:83-118.